Related Experiment Videos
Severe interstitial pneumonitis associated with docetaxel administration
William L Read1, Joanne E Mortimer, Joel Picus
1Department of Medicine, Division of Medical Oncology at Washington University, St. Louis, Missouri, USA. readw@medicine.wustl.edu
Cancer
|February 22, 2002
Summary
Interstitial pneumonitis is a rare but severe toxicity of docetaxel chemotherapy. This condition can lead to respiratory failure, requiring prolonged mechanical ventilation and potentially proving fatal.
Area of Science:
- Oncology
- Pulmonology
- Clinical Toxicology
Background:
- Docetaxel is a widely used chemotherapy agent.
- Interstitial pneumonitis is not a commonly reported side effect of docetaxel.
Observation:
- Four patients developed severe interstitial pneumonitis after docetaxel treatment.
- Symptoms included acute dyspnea and fever within 1-2 weeks of treatment.
- All patients experienced progressive interstitial infiltrates and respiratory failure.
Findings:
- The pneumonitis was attributed solely to docetaxel toxicity.
- Other causes of pneumonitis were ruled out.
- Two patients died, while survivors required extended mechanical ventilation.
Implications:
- Interstitial pneumonitis is a rare, potentially fatal complication of docetaxel.
- Early recognition and prolonged ventilatory support may be crucial for survival.